Amazon Offers This 500GB Portable External Hard Drive for Practically Free, Backed by 50K Reviews
See at Amazon
Slim and Portable Storage
The UnionSine HDD is designed for portability. For all the videographers, photographers, or any professional on the go, you'll have access to a full 500GBB of data right in your pocket—without sacrificing speed. It's compact and lightweight so you can take it with your wherever you need. It's only about the size of your wallet at about 2.5 inches. The HDD has a lovely aesthetic, with a cool brushed stripe design with rounded radians. That also makes it easy to carry. It's available in your choice of black, blue, or pink. If you pick up multiple, you can color-code the different projects your working on to make grabbing the right hard drive for the job easy.
This portable HDD is capable of read speeds up to 140M/s, write speeds up to 120M/s, and uses a USB 3.0 interface so you can transfer files to and from Windows, Mac, and Chromebooks right out of the box without needing to reformat the drive. For use with USB-C computers, an adapter will be necessary. It's even compatible with gaming consoles—specifically the Xbox One and PlayStation 4. It can handle the load times necessary for current-gen consoles, but if you're still gaming on the consoles that defined the 2010s, well you can do so now in the year 2025 with expanded storage space.
Seagate puts your security at the forefront, offering an advanced password option with hardware encryption to ensure your files and photos are protected from those you do not wish to give access.
Keep up to 500GB of photos, videos, documents, and more safely secure with the help of this portable external hard drive from UnionSine. The UnionSine 500GB Ultra-Slim HDD is normally priced at $33. However, as part of an ongoing Amazon deal, the price has been reduced by 15%. That brings the total down to just $28. It's also available in sizes of 250GB, 320GB, 750GB, 1TB, 2TB, 3TB, 4TB, and 5TB—all at varying levels of discounts.
See at Amazon
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a few seconds ago
- Associated Press
NFL Players Association executive JC Tretter is resigning amid union overhaul
WASHINGTON (AP) — NFLPA chief strategy officer JC Tretter is resigning from his position, three days after Lloyd Howell stepped down as executive director of the players' union. Tretter told CBS Sports on Sunday that he doesn't want to be considered for the NFLPA's interim executive director position and denied he played any role in undermining Howell's position. 'Over the last couple days, it has gotten very, very hard for my family. And that's something I can't deal with,' Tretter told CBS Sports on Sunday. 'So, the short bullet points are: I have no interest in being (executive director). I have no interest in being considered. I've let the executive committee know that. I'm also going to leave the NFLPA in the coming days because I don't have anything left to give the organization.' The 34-year-old Tretter, who played center for eight seasons with Green Bay and Cleveland through 2021, was the player president from 2020 to 2024. He served in his new role since October 2024. Howell resigned Thursday after two years because his leadership had become a distraction. Howell has come under scrutiny since ESPN reported he has maintained a part-time consulting job with the Carlyle Group, a private equity firm that holds league approval to seek minority ownership in NFL franchises. That followed the revelation that the NFLPA and the league had a confidentiality agreement to keep quiet an arbitrator's ruling about possible collusion by owners over quarterback salaries. The latest issue was an ESPN report Thursday that revealed two player representatives who voted for Howell were not aware that he was sued in 2011 for sexual discrimination and retaliation while he was a senior executive at Booz Allen. In 2023, a year after the NFLPA sued the owners for collusion, the NFL sued the union after Tretter suggested in an interview that running backs who were unhappy with their contracts could fake injuries, which would be a violation of the collective bargaining agreement. The grievance also was decided this year and was not shared publicly. Tretter told CBS Sports he didn't have access to the collusion grievance and wasn't involved in the confidentiality agreements. Tretter was the NFLPA's player president in 2023 when Howell was elected as the union's executive director following a vote that changed the union's constitution and made the search and election process more confidential. 'I'm not resigning because what I've been accused of is true,' Tretter said. 'I'm not resigning in disgrace. I'm resigning because this has gone too far for me and my family, and I've sucked it up for six weeks. And I felt like I've been kind of left in the wind taking shots for the best of the organization. ... And in the end, what's the organization done for me? Like, nothing.' ___ AP NFL:
Bloomberg
27 minutes ago
- Bloomberg
UK Second-Hand Shopping to Hit £4.8 Billion This Year, CEBR Says
Two-thirds of British consumers bought second-hand goods online last year, research shows, a figure expected to grow as shoppers rein in spending and as so-called 'pre-loved' items become more available. Purchases of used goods on the internet will reach £4.8 billion ($6.4 billion) in the UK this year, up from £4.3 billion in 2024, according to a report from the Centre for Economics and Business Research commissioned by Inc.
Yahoo
28 minutes ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
